Monday, February 6, 2023
Google search engine
HomeMarketResultsVaxcyte (NASDAQ:PCVX) Reaches New 52-Week High After Analyst Upgrade

Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High After Analyst Upgrade


Vaxcyte, Inc. (NASDAQ:PCVXGet Rating)’s share worth reached a brand new 52-week excessive throughout mid-day buying and selling on Tuesday after Needham & Firm LLC raised their worth goal on the inventory from $52.00 to $58.00. Needham & Firm LLC at present has a purchase ranking on the inventory. Vaxcyte traded as excessive as $48.93 and final traded at $48.78, with a quantity of 415 shares. The inventory had beforehand closed at $47.95.

PCVX has been the topic of a lot of different analysis reviews. Financial institution of America boosted their worth goal on shares of Vaxcyte to $67.00 in a analysis report on Monday, October twenty fourth. Cantor Fitzgerald boosted their worth goal on shares of Vaxcyte from $55.00 to $70.00 in a analysis report on Tuesday, November eighth. BTIG Analysis assumed protection on shares of Vaxcyte in a analysis observe on Thursday, November seventeenth. They set a “purchase” ranking and a $69.00 goal worth for the corporate. SVB Leerink reissued an “outperform” ranking and set a $60.00 goal worth on shares of Vaxcyte in a analysis observe on Friday, December sixteenth. Lastly, Guggenheim assumed protection on shares of Vaxcyte in a analysis observe on Thursday, December fifteenth. They set a “purchase” ranking and a $66.00 goal worth for the corporate.

Insider Shopping for and Promoting at Vaxcyte

In different information, Director Heath Lukatch offered 4,335 shares of the corporate’s inventory in a transaction that occurred on Thursday, November tenth. The shares have been offered at a mean worth of $46.13, for a complete worth of $199,973.55. Following the completion of the sale, the director now immediately owns 3,125 shares of the corporate’s inventory, valued at roughly $144,156.25. The sale was disclosed in a doc filed with the SEC, which is offered at this hyperlink. In different information, Director Heath Lukatch offered 4,335 shares of the corporate’s inventory in a transaction that occurred on Thursday, November tenth. The shares have been offered at a mean worth of $46.13, for a complete worth of $199,973.55. Following the completion of the sale, the director now immediately owns 3,125 shares of the corporate’s inventory, valued at roughly $144,156.25. The sale was disclosed in a doc filed with the SEC, which is offered at this hyperlink. Additionally, VP Jeff Fairman offered 10,000 shares of the corporate’s inventory in a transaction that occurred on Wednesday, October twenty sixth. The inventory was offered at a mean worth of $40.00, for a complete transaction of $400,000.00. Following the completion of the sale, the vp now immediately owns 286,227 shares of the corporate’s inventory, valued at $11,449,080. The disclosure for this sale could be discovered here. Insiders offered 29,485 shares of firm inventory valued at $1,073,063 within the final ninety days. Firm insiders personal 13.70% of the corporate’s inventory.

Institutional Buying and selling of Vaxcyte

Quite a lot of hedge funds and different institutional buyers have not too long ago made modifications to their positions in PCVX. Swiss Nationwide Financial institution raised its holdings in shares of Vaxcyte by 8.9% within the 1st quarter. Swiss Nationwide Financial institution now owns 50,000 shares of the corporate’s inventory value $1,208,000 after buying a further 4,100 shares within the final quarter. JPMorgan Chase & Co. raised its holdings in shares of Vaxcyte by 31.3% within the 1st quarter. JPMorgan Chase & Co. now owns 26,792 shares of the corporate’s inventory value $647,000 after buying a further 6,390 shares within the final quarter. Financial institution of New York Mellon Corp raised its holdings in shares of Vaxcyte by 4.7% within the 1st quarter. Financial institution of New York Mellon Corp now owns 152,364 shares of the corporate’s inventory value $3,680,000 after buying a further 6,891 shares within the final quarter. MetLife Funding Administration LLC raised its holdings in shares of Vaxcyte by 58.5% within the 1st quarter. MetLife Funding Administration LLC now owns 23,689 shares of the corporate’s inventory value $572,000 after buying a further 8,743 shares within the final quarter. Lastly, Rhumbline Advisers raised its holdings in shares of Vaxcyte by 8.2% within the 1st quarter. Rhumbline Advisers now owns 50,789 shares of the corporate’s inventory value $1,227,000 after buying a further 3,852 shares within the final quarter. 71.50% of the inventory is at present owned by institutional buyers.

Vaxcyte Buying and selling Up 0.8 %

The enterprise’s fifty day transferring common is $44.38 and its 200 day transferring common is $31.60. The agency has a market capitalization of $3.83 billion, a P/E ratio of -16.48 and a beta of 1.04.

Vaxcyte (NASDAQ:PCVXGet Rating) final launched its quarterly earnings outcomes on Monday, November seventh. The corporate reported ($0.93) earnings per share (EPS) for the quarter, lacking analysts’ consensus estimates of ($0.80) by ($0.13). As a bunch, sell-side analysts predict that Vaxcyte, Inc. will submit -3.25 earnings per share for the present fiscal yr.

Vaxcyte Firm Profile

(Get Rating)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine firm, develops novel protein vaccines to forestall or deal with bacterial infectious illnesses. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that’s in Section 1/2 medical trials to deal with invasive pneumococcal illness and pneumonia.

Learn Extra

This on the spot information alert was generated by narrative science know-how and monetary knowledge from MarketBeat so as to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you contemplate Vaxcyte, you may need to hear this.

MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Vaxcyte wasn’t on the record.

Whereas Vaxcyte at present has a “Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments